Chanelle Group, the largest Irish-owned manufacturer of generic pharmaceutical products in Ireland opened its new €10 million spot on manufacturing facility last Thursday (September 6th)
Tánaiste and Minister for Foreign Affairs and Trade, Simon Coveney, T.D cut the ribbon on the new 30,000 sq. ft. facility - Europe’s first dedicated Spot On manufacturing facility - at Loughrea, Co. Galway.
The company founder and director also announced details of a new €11 million 25,000 sq ft manufacturing facility.
“We will invest €11 million in a new facility for the manufacture of liquid and paste products which will also be designed and built to European and US quality standards.”
Construction will begin in October 2019 and the products manufactured will be for the US market.
The company expects to create an additional 350 new jobs over the next five years, investing some €86 million in its operations.
Chanelle Group achieved sales over €111 million in 2017 and is forecasting sales of €130 million in 2018; Chanelle Group trades with over 90 countries worldwide and employs over 500 people at present.
Speaking at the official opening, the Tánaiste - Simon Coveney, TD said;
“The company’s pioneering approach to product innovation has been a key factor in the company’s substantial growth in recent years. With over 96 products in its R&D pipeline, Chanelle is well positioned to continue to expand into new markets.”
Research and Development
Michael Burke, Owner and Managing Director of Chanelle Group said:
“Research and Development is critical to our success. We’ve doubled turnover in the last five years and expect to double turnover again within the next five years.”
The company will invest more than €45 million in R&D over the next five years in its five research laboratories operating in Ireland and the Middle East; the company develops 15 to 20 new products every year.
Leadership and Innovation
Julie Sinnamon, CEO, Enterprise Ireland said:
“Chanelle’s success is a testament to the innovation and leadership at Chanelle. Enterprise Ireland will continue to work with Chanelle to achieve its global ambition, cementing the company as a global leader in its field, and creating and sustaining regional jobs in Ireland.”
The new Spot On manufacturing facility will enable Chanelle Group to grow its share of the global market in anti-parasitic health products for small animals which is expected to reach a value of $2.28 bn by 2026.
The rapid growth in market demand is due to increasing spending by pet owners on healthcare for their pets.
Increasing disposable income enables them to spend more generously on pet care than ever before. Chanelle has agreed Spot On manufacturing contracts in excess of €20 million, with animal health companies in the EU; Asia; the Middle East and the United States.
Chanelle has designed and built the new Spot On manufacturing facility to meet HPRA and FDA standards.
Roles at the Spot-On manufacturing facility include positions in Operations; Research & Development; Engineering; Quality and Warehouse operations.